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Characterization of Thyroid-Stimulating Blocking Antibodies
That Appeared During Transient Hypothyroidism After
Radioactive Iodine Therapy
Annie W.C. Kung,1 K.S. Lau,1 and LD. Kohn2
Hypothyroidism after radioactive iodine (RAI) therapy for Graves' disease can be transient or permanent. The
cause for early transient hypothyroidism is unknown. We evaluated 11 patients who developed transient hy¬
pothyroidism within 6 months of RAI and 12 who remained euthyroid after RAI. Approximately equal num¬
bers of patients in each group had thyroid-stimulating antibody (TSAb) that increased cyclic adenosine
monophosphate (cAMP) levels in Chinese hamster ovary (CHO) cells transfected with the recombinant human
thyrotropin receptor (TSHR) (WT cells). Approximately equal numbers of patients from both groups had an
increase in TSAb activity post-RAI. All TSAbs had their dominant functional epitope on the N-terminus of the
TSHR extracellular domain, requiring residues 90-165 for activity because they, but not TSH, completely lost
stimulating activity in a receptor chimera, wherein TSHR residues 90-165 were substituted by equivalent
residues of the lutropin/choriogonadotropin receptor (LH/CGR). Although equal numbers of patients in both
groups had thyrotropin-binding inhibiting immunoglobulin activity (TBII), as measured by radioreceptor as¬
say before RAI, patients with transient hypothyroidism had a surge in TBII activity and all except one became
positive for thyroid-stimulating blocking antibodies (TSBAb), as measured by inhibition of TSH-stimulated
cAMP from WT cells. When immunoglobulin G (IgGs) were epitope-mapped using TSHR/LH-CGR chimeras
with different substitutions, 8 hypothyroid subjects had TSBAbs directed against residues 90-165 of the TSHR,
as well as TSHR residues 261-370. Two had functional epitopes directed at residues 9-89 as well as TSHR
residues 261-370. None of the euthyroid control patients developed TSBAbs and their TBII activity decreased
post-RAI. When patients with transient hypothyroidism reverted to a euthyroid state, TSAb was still detectable
in 5; however, TBII was present in all and TSBAb, although decreased, was still positive in 9. In summary, RAI
therapy was associated with a change in thyroid antibody characteristics in most patients. Additionally, pa¬
tients with a surge in TBII and the appearance of TSBAb developed transient hypothyroidism after RAI.
Introduction do not require life-long thyroxine (T4) replacement therapy.
The cause of transient hypothyroidism after RAI was
Radioactive iodine therapy (RAI) is used as the therapy thought to be caused by a short-lived organification defectof choice for hyperthyroidism due to Graves' disease. (3). However, it has been suggested by ourselves and others
With better understanding of the safety of RAI, it is even pre- that the transient development of hypothyroidism could be
scribed more frequently for younger patients as the first-line related to changes in antibody parameters. With the avail-
treatment of choice. Hypothyroidism commonly develops af- ability of more specific tests for characterization of the an-
ter RAI. The incidence of permanent hypothyroidism after tithyroid antibodies, it was observed that RAI could result
RAI increases with time but is largely dependent on the dose in alteration of the antibody profiles and that the resulting
of 131I administered (1,2). In the majority of cases, hypothy- change in antibody profiles could lead us to a change in the
roidism is caused by radiation damage to the thyroid. clinical status of the patients (4,5). A transient surge in thy-
Approximately 10% to 15% of patients may, however, de- rotropin-binding inhibitory immunoglobulin (TBII) has been
velop transient hypothyroidism a few months after RAI, but seen in patients with Graves' disease (6); however, the TBII
department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong,
^ell Regulation Section, Metabolic Diseases Branch, NIDDK, Bethesda, Maryland.
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activity did not correlate with the thyroid-stimulating anti¬
body (TSAb) activity as measured by cyclic adenosine
monophosphate (cAMP) release from thyroid cells (7). Re¬
cently, Michelangeli et al. (8) reported that hypothyroidism
after RAI could be associated with the production of thyroid-
blocking antibodies but did not further characterize these.
In the present study, we studied patients who developed
transient hypothyroidism after a low to moderate dose of
RAI, evaluated their thyrotropin receptor (TSHR) antibody
profile, and correlated changes in TSHR antibodies with the
clinical thyroid status. In order to evaluate the TSHR anti¬
body profiles, we measured TBII activity, thyroid-stimulat¬
ing TSHR antibodies, and three different types of thyroid-
stimulating blocking antibodies in each patient's sera. The
stimulating and blocking TSHR antibodies were measured
using Chinese hamster ovary (CHO) cells transfected with
wild-type human TSHR or transfected with several TSHR
lutropin/choriogonadotropin receptor (LH/CGR) chimeras:
Mel + 2, Mc2, and Mc4. The Mel + 2, Mc2, and Mc4
chimeras substitute, respectively, TSHR residues 9-165,
90-165, and 261-370 with equivalent residues of the
LH/CGR. Using this panel, the following functional
TSHRAbs can be separately measured (9-17). TBIIs in
Graves' patients whose functional epitopes are on the N-ter¬
minus of the extracellular domain, which can block TSH ac¬
tivity, and that are directed at TSHR residues 90-165 or 9-89;
TBIIs whose functional epitopes are on the C-terminal por¬
tion of the extracellular domain, residues 261-370, which
block stimulating TSHR antibodies as well as TSH activity
and that are associated with hypothyroidism in patients with
idiopathic myxedema or Hashimoto's thyroiditis; stimulat¬
ing TSHR antibodies whose activity is dependent on the N-
terminus of the extracellular domain and are the predomi¬
nant functional epitope in 95% of Graves' patients;
stimulating TSHR antibodies whose epitope is heteroge¬
neous and involves epitopes other than on the N-terminus
(9-165), although their predominant epitope remains on the
N-terminus, have been reported to have diagnostic and ther¬
apeutic implications in patients receiving methimazole treat¬
ment (10,11).
Patients and Methods
Patients
The subjects were part of a group of 120 patients recruited
to study the factors that determine hypothyroidism after RAI(18). The diagnosis of Graves' disease was based on clinical
assessment, a diffuse increased uptake on thyroid scan, and
elevated total serum T4 level or free thyroxine index (FTI).
The dose of RAI was intended to deliver 80 Gy to the thy¬
roid gland and was calculated according to the formula of
Blomfield et al. (19). The thyroid gland size was estimated
by scan using Goodwin's formula (20). Among these 120 pa¬
tients, 11 subjects who developed transient hypothyroidism
were studied. They had low free thyroxine (FT4) and ele¬
vated TSH within the first 6 months after RAI treatment, but
subsequently became and remained euthyroid at 1 year. Sera
were taken before RAI, during hypothyroidism, and at eu¬
thyroidism. Twelve subjects who received similar RAI ther¬
apy during the same period but remained euthyroid after¬
wards were also studied before, at 6 months, and 12 months
after RAI. All patients were followed for at least 5 years and
were documented euthyroid by regular thyroid function test
monitoring.
Immunoglobulin G preparation
Sera were stored at -70°C until immunoglobulin G (IgG)
preparation. IgGs were extracted by affinity chromatogra-
phy using protein A-Sepharose CL-4B columns (Amersham
Pharmacia, Piscataway, NJ) followed by dialysis. The purity
of the IgG preparation was confirmed by documentation of
immeasurable TSH levels.
Thyroid autoantibody assays
Thyroid-stimulating antibody (TSAb) was determined in
purified IgG by measuring cAMP released from Chinese
hamster ovary (CHO) cells stably transfected with wild-type
human TSHR (WT cells) as described (9-13). In brief, assays
were performed in NaCl-free HBSS containing 20 mmol/L
of HEPES (pH, 7.4), 1% bovine serum albumin (BSA), of 0.5
mmol/L of 3-isobutyl-L-methylxanthine, and 222 mmol/L of
sucrose to make incubations isotonic. Bovine thyrotropin(bTSH), 1 mU/mL (Sigma, St. Louis, MO), or purified IgG,
1.5 mg/ml, dissolved in 300 ^.L of incubation media and in¬
cubated with cells for 2 hours at 37°C. Supernatants were as¬
pirated and stored at -20°C; cAMP released into the
medium was measured by RIA. TSAb activity was expressed
as the percentage increase in cAMP levels in the experi¬
mental IgG relative to pooled IgG from 20 normal individ¬
uals.
Thyroid-stimulating blocking antibody (TSBAb) was de¬
termined by IgG-induced inhibition of the TSH-stimulated
cAMP response to CHO-hTSHR cells (WT cells) as reported
previously (10-12). To calculate TSBAb activity, the follow¬
ing formula was used: 100% X (1
-
[(cAMP accumulation in
the presence of TSH and test IgG)/cAMP accumulation in
the presence of TSH (1 mlU/L) and normal IgG)]}. To char¬
acterize the blocking activity of the IgG further, the Ig were
also evaluated using Mel + 2, Mc2, and Mc4 cells. Mel + 2
cells are CHO cells transfected with an hTSHR-LH/CGR
chimera in which residues 9-165 of TSHR were replaced by
residues 101-166 of the LH/CGR. In Mc2 cells, TSHR
residues 90-165 were replaced by residues 91-166 of the
LH/CGR. In Mc4 cells, TSHR residues 261-370 were re¬
placed by residues 261-329 of the LH/CGR. In Mc4 cells,
TSBAb activity was measured using a TSAb as the stimula¬
tor rather than TSH, with otherwise identical calculations.
TBII was determined in patients' sera by inhibition of spe¬
cific [125I] bTSH binding to porcine thyroid membranes in a
radioreceptor assay (RSR, Cardiff, UK). Assay results were
expressed in terms of inhibition of TSH binding, calculated
as follows: 100% x {1
—
(labeled TSH specifically bound in
the presence of test serum/labeled TSH specifically bound
in the presence of normal serum)).
Triplicate assays were performed on all samples for anti¬
body assays. The cAMP RIA assays (Incstar Corp., Stillwa-
ter, MN) were performed in duplicate. The normal ranges in
20 healthy subjects for TBII, TSAb, and TSBAb were +15%
to -15%, 60%-145%, and -15% to +20%, respectively. The
determination of TSAB and TSBAb in the same sample was
performed in the same assay. The intraassay and interassay
coefficients of variance for TBII, TSAb, and TSBAb were 5.0%
and 8.6%, 6.0% and 8.9%, and 9.7% and 11.6%, respectively.
APPEARANCE OF TSAb DURING TRANSIENT HYPOTHYROIDISM 911
Statistics
Comparisons between hypothyroid patients and euthy¬
roid controls were performed using two-way analysis of
variance (ANOVA). Comparison within groups were per¬
formed using two-sample t tests or Wilcoxon ranks test de¬
pending on the distribution of the data.
Results
The patients examined in this study were all those who
developed transient hypothyroidism during a study of 120
consecutive Graves' patients treated with RAI (9). Control
patients were all those in the same study who were euthy¬
roid after RAI. They were of similar age and gender. They
had no significant difference in onset of hyperthyroidism,
thyroid hormone or TSH levels, levels of thyroglobulin TG
or thyroid peroxidase (TPO) antibodies, thyroid size, and
RAI dose (Table 1). The clinical characteristics of patients
who developed transient hypothyroidism or remained eu¬
thyroid after RAI and were studied in this report were, there¬
fore, similar. For those with transient hypothyroidism, the
mean time to develop hypothyroidism was 4.5 ±1.8 months
after RAI. Thus, control patients and those with transient hy¬
pothyroidism were evaluated at a similar interval after ra¬
dioiodine therapy in the assays to follow.
In the patients with transient hypothyroidism, TSAb ac¬
tivity, measured by WT cells was positive in 6 patients be¬
fore RAI (Fig. 1; Table 2, bold). Eight patients had TBII ac¬
tivity before RAI and one subject had TSBAb (Fig. 1; Table
2, bold). During transient hypothyroidism, an increase in
TSAb was observed in four subjects (Table 2; starred). All
except one subject was positive for TSBAb; and all patients
had a surge in TBII titer (Fig. 1; Table 2, starred). At euthy¬
roidism, TSAb was still detectable in five subjects (Table 2,
bold); however, although all patients were positive for TBII
and eight subjects were positive for TSBAb, the titers of each
had decreased (Table 2, double starred for individuals with
significant reduction in blocking TSHRAb and TBII activity
at euthyroidism). As a group, significant differences in the
median values of TSAb (p < 0.05), TSBAb (p < 0.001), and
TBII (p < 0.0005, contrast from ANOVA for repeated
measures) could be detected in these patients before RAI,
during transient hypothyroidism, and at euthyroid state(Table 2).
In the 12 control patients who remained euthyroid after
RAI, TSAb measured with WT cells was present in 5 sub¬
jects before RAI, an approximately equal number as in the
patients who would develop transient hypothyroidism (Fig.
1; Table 2, bold). Three patients remained positive for TSAb
at 6 months and 6 at 12 months (Fig. 1; Table 2, bold). All
control subjects were negative for TSBAb throughout the
study (Fig. 1; Table 2). Ten control subjects had TBII activity
before RAI, but there was no major surge in these activities
at 6 or 12 months, comparable to the surge in TBII values in
the patients with transient hypothyroidism (Table 2). There
was no significant difference in the median values of TSAb,
TSBAb, and TBII in these control patients before and after
RAI (Table 2).
For those patients with transient hypothyroidism, their
median TSBAb and TBII values but not TSAb at the time of
transient hypothyroidism as well as during euthyroidism
were significantly higher than those values of the control pa¬
tients taken at a similar time point after RAI (Table 2).
Stimulating TSAbs
We characterized the stimulating TSAb epitopes in all pa¬
tients positive for TSAbs at the start of therapy, those with
transient hypothyroidism, or their matched euthyroid con¬
trols. Overall, the median values for TSAb activity measured
in the various cell lines were similar between the two groups(Table 3). There was a complete loss in the ability of the stim¬
ulating TSAb to increase cAMP levels in Mc2 cells. Values
with significant losses by comparison to wild-type values(p < 0.05) are starred (Table 3). Mc2 cells have TSHR residues
90-165 substituted by the homologous LH/CGR residues.
Similarly, there was a complete loss of TSAb activity in
Mel + 2 cells, which had TSHR residues 9-165 substituted
(Table 3, starred,
 
< 0.05). Although stimulating TSHRAb
activity increased in some patients post-RAI therapy (Table
2), epitope mapping did not reveal a significant change in
these data.
Thus, the stimulating autoantibodies had the major por¬
tion of their functional epitopes directed against the N-ter-
minal portion of the extracellular domain of TSHR and re¬
quired expression of residues 90-165 of TSHR for their
activity. Moreover, in all patients with stimulating TSHR an¬
tibodies, the stimulators appeared to have the same charac¬
teristics in both control patients and those with transient hy¬
pothyroidism.
Of interest, the ability of all the stimulating TSAb to in¬
crease cAMP levels in Mc4 cells was similar to that noted in
Table 1. Clinical Characteristics of Patients with Graves' Hyperthyroidism Given Radioactive Iodine (RAI)
who Developed Transient Hypothyroidism vs. Paired Control Patients who Remained Euthyroid
Transient hypothyroidism Euthyroid controls
No. of patients (M/F)
Mean age (range) (yr)
Onset of hyperthyroidism (months)
Serum FT4 (pmol/L)
Serum TSH (mlU/L)
Mean anti-Tg titer (range)
Mean anti-TPO titer (range)Estimated thyroid volume (mL)
Radioactive iodine dose (MBq)
 (3/8)
48 (32-68)
4.7 ± 2.3
64 ± 37
All <0.03
400 (<100-25,600)
6400 (<100-25,600)
38 ± 27
371 ± 158
12 (3/9)
51 (36-71)
4.6 ± 3.1
68 ± 35
All <0.03
400 (< 100-25,600)
6400 (<100-25,600)
35 ± 30
386 ± 179
 
all = not significant.
FT4, free thyroxine; TSH, thyrotropin; Tg, thyroglobulin; TPO, thyroid peroxidase.
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FIG. 1. Thyroid stimulating antibody (TSAb) as measured by cyclic adenosine monophosphate (cAMP) release. Thyroid
autoantibodies in patients developing transient hypothyroidism after radioactive iodine (RAI) therapy and in a matched
set of patients who remained euthyroid. In Chinese hamster cells (CHO) transfected with the extracellular domain of the
thyrotropin receptor (TSHr) (WT cells) (a, b), Thyroid stimulating-blocking antibody (TSBAb) as determined by inhibition
of TSH-stimulated cAMP response by immunoglobulin G (IgG) samples in WT cells (c, d). Thyroid-binding inhibitory im¬
munoglobulin (TBII) as measured by radioreceptor assay (e, f). The panels show transient hypothyroid subjects before RAI
treatment, during hypothyroidism and at euthyroidism (a, c, e). Euthyroid controls (b, d, f) were studied before, and at 6
and 12 months after RAI. All values represent the mean of three determinations performed in triplicate and with duplicate
cAMP RIAs, as noted in Materials and Methods and Table 2. Exact values are presented in Table 2.
WT cells (Table 3). This, plus the complete loss of stimulat¬
ing TSAb activity in the Mel+2 and Mc2 chimeras, suggested
that TSHR residues 261-370 are not involved in the epitope
for these TSAbs.
Blocking TSBAbs
To characterize the blocking activity of the IgG of patients
with transient hypothyroidism, IgGs prepared at the time of
hypothyroidism were incubated with purified bTSH (1
mU/mL) in WT, Mel +2, and Mc2 CHO cells or with a stan¬
dard TSAb in CHO cells with the Mc4 chimera (Table 4).
During transient hypothyroidism, the ability of the IgG to
inhibit the stimulatory activity of TSH was lost in 10 patients
when their IgG was incubated with Mel +2 cells and in 8 pa¬
tients when their IgG was incubated with Mc2 cells (Table
4, starred,
 
< 0.001 and <0.05, respectively). The ability of
the 10 TSBAb-positive IgG to inhibit the stimulatory activ¬
ity of Graves' IgG was also lost in Mc4 cells (p < 0.001). This
pattern is characteristic of a TSBAb that has its functional
epitope directed against residues 90-165 of the N-terminus
of the TSHR extracellular domain as well as TSHR residues
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Table 3. Stimulating TSHR Antibody Activity before RAI Measured in CHO Cells Transfected with
Wild-Type (WT) Human TSHR or the Mc2, Mel+2, and Mc4 TSHR/LH CGR Chimeras
Patient
IgG
Stimulating
TSHR antibody
in WT CHO-TSHR
Cells
(% ofNl. IgG)
Stimulating TSHR
antibody in
Mcl+2 CHO-TSHR
Cells*
(% ofNl. IgG)
Stimulating
TSHR antibody
in Mc2 CHO-TSHR
Cells*
(% ofNl. IgG)
Stimulating
TSHR antibody
in Mc4 CHO-TSHR
Cells
(%ofNl. IgG)
Nl IgG
TH1
TH2
TH3
TH4
TH5
TH6
TH7
TH8
TH9
TH10
TH11
Median
(interquartile
range)
Cl
C2
C3
C4
C5
C6
C7
C8
C9
C10
CH
C12
Median(interquartile
range)
100
492
141
1550
337
145
345
76
517
86
159
69
159 (86, 492)
67
94
76
412
160
531
225
119
263
78
73
109
114 (76, 253)
100
98*
86
73*
54*
67
78*
93
108*
98
86*
97
86 (73, 98)
60
76
70
68*
77*
70*
62*
73
78*
70
77
59
70 (63, 76)
100
78*
107
86*
112*
104
108*
96
86*
78
103*
87
96 (86, 107)
60
67
68
62*
60*
64*
68*
62
70*
61
67
69
65 (61, 68)
100
252
128
1257
286
112
301
62
378
76
136
62
136 (76, 301)
56
86
70
380
150
389
187
108
245
70
68
87
97 (70, 230)
Mcl+2 and Mc2 cells were responsive to TSH, similar to wild-type cells, as previously described (9-13,15-17). TH, transient hypothyroid
patients; C, control patients. All values represent the mean of three determinations performed in triplicate and with duplicate cAMP RIAs,
as noted in Materials and Methods. Positive antibody activities are in bold. * values with significant losses by comparison to wild-type values(p < 0.05). Median values of TSHR antibody activity measured in different cells lines were similar between two groups.TSHR, thyrotropin receptor; RAI, radioactive iodine; CHD, Chinese hamster ovary; LH/CGR, lutropin/choriogonadotropin receptor.
261-370 in 8 patients. In 2 patients who lost their inhibitory
activity in Mel +2 cells but retained inhibitory activity in Mc2
cells, the functional TSBAb epitope is directed against the
residue 9-90 of the  terminus of the TSHR extracellular do¬
main as well as TSHR residues 261-370.
At euthyroidism, the activity of the blocking TSBAb in WT
cells significantly decreased in eight patients (p < 0.001), re¬
mained similar in two, and slightly increased in one subjects(Fig. 1 Table 2). The activity of the two patients with block¬
ing action in Mc2 cells also decreased (patient 2, from 39% ±
6% to 25% ± 10%; patient 10, from 70% ± 11% to 21% ±
16%). Similar to the time at hypothyroidism, no inhibitory
activity was observed with any of the IgG at euthyroidism
when inculated in Mcl+2 and Mc4 cells. These results sug¬
gested that there was no change in the TSBAb epitope even
with the change in hormonal status of the patients.
Discussion
Hypothyroidism is the most common result of RAI therapy
for thyrotoxicosis. With graded doses of 131I therapy given ac¬
cording to the thyroid gland size and activity, the incidence of
hypothyroidism in the first year is 10%. Thereafter, a 3% an¬
nual cumulative incidence of hypothyroidism is seen due to
chronic gradual thyroid atrophy (21). Among those who de¬
velop early and permanent hypothyroidism, 80%-85% de¬
velop the disease as a function of the dose of 131I, i.e., because
of higher or ablative doses resultant from our inability to cal¬
culate the exact response to RAI in different individuals. One-
third of U.S. thyroidologists considered hypothyroidism as the
desired end point of RAI therapy because they believe this
would avoid the risk of recurrent thyrotoxicosis and is also an
easier management problem (22). This is, however, controver¬
sial because it has the net effect of treating one disease by cre¬
ating a second, with its own attendant complications and risks.
This report does not attempt to address this complicated issue,
but rather focuses on the 10% to 15% of RAI patients develop
transient, rather than permanent hypothyroidism, and do not
require life-long T4 replacement therapy. We questioned
whether the basis for this might be the development of an un¬
usual subtype of TSHR antibodies.
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Table 4. Blocking TSHRAb Activity of Patients with Transient Hypothyroidism (TH) Measured in CHO Cells
Transfected with Wild-Type (WT) Human TSHR or the Mc2, Mcl+2, and Mc4 TSHR/LH CGR Chimeras
Before RAI
Patient
IgG
TSH Blocking
TSHRAb Activity
in WT CHO-
TSHR Cells
(% Inhibition)
Graves' IgG
Blocking TSHRAb
Activity in WT
CHO-TSHR Cells
(% Inhibition)
TSH Blocking
TSHRAb Activity
in Mcl+2
CHO-TSHR Cells
(% Inhibition)
TSH Blocking
TSHRAb Activity
in Mc2
CHO-TSHR Cells
(% Inhibition)
Graves' IgG
Blocking TSHRAb
Activity in Mc4
CHO-TSHR Cells
(% Inhibition)
Nl IgG
TH1
TH2
TH3
TH4
TH5
TH6
TH7
TH8
TH9
TH10
TH11
Median
(interquartile
range)
Nl IgG
TH1
TH2
TH3
TH4
TH5
TH6
TH7
TH8
TH9
TH10
TH11
Median
(interquartile
range)
<20
19
20
16
13
-17
51
12
11
2
13
15
13 (11, 19)
<20
34
90
12
89
81
56
30
35
35
96
57
56 (34, 89)*
<20
14
-17
12
-11
-13
43
-10
-26
7
-11
10
-10 (- 13, 12)
<20
28
54
10
70
42
23
26
28
26
70
34
28 (26, 54)*
<20
10
-15
10
12
-17
-21*
17
-18
3
-15
17
3(- 17, 12)
<20
-10*
-5*
-10
-7*
-2*
-7*
10*
-9*
-7*
-10*
-17*
7 (10, 5)++
<20
-17
-13
-16
10
-2
-17*
15
10
6
-12
11
-2 (-16, 10)
<20
-20"
39
-25
-15"
-10"
-10"
-11"
-10"
-12"
70
-19"
-11 (-19, -10)+
<20
-25
11
17
14
2
10*
-10
7
-11
10
15
10 (- 10, 14)
<20
-15*
-20*
-17
-8*
-17*
-17*
5*
-12*
-11*
7*
-10*
-12 (-17, -8)+
All values represent the mean of three determinations performed in triplicate and with duplicate cAMP RIAs, as noted in Materials and
Methods. Positive blocking activities are in bold. * values with significant losses by comparison to wild-type values (p < 0.05 or better).
+,
 
< 0.05; n,p < 0.001, median values compared to wild type values, a,  < 0.001, median values compared to values before RAI.
Our results demonstrate that transient hypothyroidism af¬
ter RAI in most patients is associated with a significant surge
of blocking antibody (TSBAb) activity in association with a
significant surge in TBII activity and, more important, that
the blocking TSHR antibody has a hybrid functional epitope
directed against residues 261-370, as well as residues 90-165
or 9-89 of the TSHR, i.e., against an epitope associated with
hypothyroidism in some patients with idiopathic myxedema
or Hashimoto's thyroiditis. Because the TSBAb and TBII ac¬
tivities decrease with time, these patients only developed
transient, not permanent hypothyroidism.
Previous studies have reported that RAI treatment is as¬
sociated not only with changes in the level of TSHR anti¬
bodies, but also with changes in the characteristics of the an¬
tibodies. McGregor et al. (6) reported an increase in TBII after
RAI, and that a surge in TBII was associated with a higher
chance of post-RAI hypothyroidism. Because TBII and TSAb
activities did not correlate with each other in studies of this
period (7), the authors of those studies postulated that the
discrepancy could be due to blocking antibodies (6,7).
Michelangeli et al. (8) subsequently reported that in their pa¬
tients with hypothyroidism occurring within 6 months of
RAI, blocking antibodies were present in 75% of hypothy¬
roid patients, half of whom had transient hypothyroidism.
It was not specifically mentioned whether their patients with
transient hypothyroidism had TSAb activity, nor how many
had preexisting blocking or TBII antibodies before RAI, nor
what type of blocking TSHR antibody was present. Never¬
theless, their data suggested that blocking TSAbs played an
important role in causing the hypothyroidism in a signifi¬
cant fraction of these patients, whether hypothyroidism was
transient or permanent in nature.
In our present series of patients with transient hypothy¬
roidism, only one patient had TSBAb before RAI, but all ex¬
cept one subject were positive for TSBAb at the time of hy¬
pothyroidism. Similar to the observation of McGregor et al.(6), all patients had a surge in TBII activity at the time of hy¬
pothyroidism. The development of TSBAb activity in asso¬
ciation with the surge in TBII activities suggests the two ac¬
tivities are linked and reflect a unique population of thyroid
autoantibodies. This would be consistent with previous ob¬
servations (6,12,14).
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Our findings and those in the report by Michelangeli et al.(8) do not contradict those of Chivato et al. (23). Chivato et
al. (23), using a much higher dose of RAI, detected TSBAb
in only 29% of their patients with hypothyroidism. However,
the cause of hypothyroidism after high-dose RAI therapy in
that series is probably due to radiation destruction of the thy¬
roid in many cases and mostly permanent in nature. In a ret¬
rospective study, Yoshida et al. (24) identified blocking an¬
tibodies only in patients who developed early permanent
hypothyroidism but not late hypothyroidism.
In this report, we extend previous observations by char¬
acterizing the blocking TSHR antibodies developing in as¬
sociation with the transient hypothyroidism. The blocking
antibodies in our patients exhibited an unusual behavior. In
all cases, the blocking antibodies were directed against a hy¬
brid conformational epitope involving the N- as well as C-
terminal parts of the extracellular domain. Thus the major¬
ity were directed against residues 90-165 and residues
261-370, because they lost blocking activity in Mc2 cells,
where 90-165 were mutated and in Mc4 cells where residues
261-370 are lost. A minority was however directed against
residues 9-89 and residues 261-370, because they lost block¬
ing activity in Mcl+2 but not Mc2 cells as well as in Mc4
cells. The former antibodies can be construed as similar to
the type I TBII in Graves' disease as described previously by
Watanabe et al. (14), because those lose TBII and blocking
activity in Mc2 cells. However, those types of blocking re¬
ceptor autoantibodies do not appear to affect the ability of a
stimulating TSHR antibody to induce hyperthyroidism, only
the activity of TSH (12,14). In the present case, the blockers
are also directed at the C-terminus, based on the loss of ac¬
tivity in Mc4 chimeras, in which region TBIIs with blocking
activity against TSAbs have been described (12,14). No Mc4
data were presented in the Watanabe et al. (14) report. This
kind of antibody might be predicted to exhibit conversion
activity, wherein anti-IgG could convert the blocker into a
stimulator (12,14). Unfortunately due to limited IgG supply
in our study, we could not determine the conversion activ¬
ity of these sera.
Two patients had blocking antibodies that were directed
against residues 9-89 of the TSHR similar to some Graves'
TBII, termed type II and described previously (12). This kind
of Graves' antibody can activate the inositol phosphate sig¬
nal transduction system. Unfortunately due to limited Ig
supply in our study, we could not determine the ability of
these IgGs to activate the inositol phosphate or arachidonate
signal transduction system (12,16).
The transient appearance of these antibodies together with
the character of these antibodies may explain why the hy¬
pothyroidism observed in these patients was only transient
in nature. Current studies are aimed at further characteriz¬
ing the blocking TSHR antibodies using monoclonals to see
if these activities represent a single antibody preparation or
a heterogeneous population. These data will be needed to
resolve questions concerned with specific blocking TSHR an¬
tibody activities on specific TSAbs, each with defined but po¬
tentially different epitopes. In all patients with stimulating
TSHR antibodies, the stimulators appeared to have the same
characteristics in both control patients and those with tran¬
sient hypothyroidism, i.e., they had a homogeneous epitope
on the N-terminus of the TSHR. Current experiments are be¬
ing performed to epitope map stimulating TSHR antibodies
in patients pre-RAI and post-RAI who develop permanent
hypothyroidism to see if this is a unique feature of this group.
In conclusion, we have demonstrated the existence of het¬
erogeneous antibodies present in patients with Graves' dis¬
ease treated with RAI. The TSAb activities were directed
against N-terminal portion of the TSHR extracellular domain
and they require residues 90-165 for activity. Early transient
hypothyroidism after RAI was associated with the tempo¬
rary appearance of blocking antibody activities in most pa¬
tients. Two kinds of blocking activities were seen, with one
having a functional epitope on residues 90-165 of TSHR and
another having an epitope involving residues 9-89 of the
TSHR, but both have another epitope on residues 261-370.
How RAI alters the profile of antithyroid antibodies is un¬
certain. It is most likely that RAI causes a release of thyroid
antigen from the damaged cells, which results in the stimu¬
lation of different clones of lymphocytes producing hetero¬
geneous antibodies that exhibit diversity in their ability to
increase cAMP and in blocking TSHR binding or activity.
The result causes diversity in the clinical course of the pa¬
tients after RAI treatment.
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